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Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretro-
viral therapy in infants and children to treat HIV infection. Dosing based on either weight or body surface area has been ap-
proved by the U.S. Food and Drug Administration (FDA) but can be difficult to implement in resource-limited settings. The
World Health Organization (WHO) has developed simplified weight band dosing for NVP, but it has not been critically evalu-
ated. NVP pharmacokinetic data were combined from eight pediatric clinical trials (Pediatric AIDS Clinical Trials Group
[PACTG] studies 245, 356, 366, 377, 403, 1056, and 1069 and Children with HIV in Africa Pharmacokinetics and Adherence of
Simple Antiretroviral Regimens [CHAPAS]) representing subjects frommultiple continents and across the pediatric age contin-
uum. A population pharmacokinetic model was developed to characterize developmental changes in NVP disposition, identify
potential sources of NVP pharmacokinetic variability, and assess various pediatric dosing strategies and their impact on NVP
exposure. Age, CYP2B6 genotype, and ritonavir were independent predictors of oral NVP clearance. The Triomune fixed-dose
tablet was an independent predictor of bioavailability compared to the liquid and other tablet formulations. Monte Carlo simu-
lations of the final model were used to assessWHOweight band dosing recommendations. The final pharmacokinetic model
indicated thatWHOweight band dosing is likely to result in a percentage of children with NVP exposure within the target range
similar to that obtained with FDA dosing. Weight band dosing of NVP proposed by theWHO has the potential to provide a sim-
ple and effective dosing strategy for resource limited settings.
Nevirapine (NVP) is a nonnucleoside reverse transcriptase in-hibitor (NNRTI) used worldwide as part of antiretroviral
therapy. NVP in combination with two nucleoside/nucleotide re-
verse transcriptase inhibitors (NRTIs) is recommended by the
World Health Organization (WHO) for first-line therapy in in-
fants 24 months of age and in infants 24 months of age who
were not exposed to maternal or infant NVP or other NNRTIs
used for maternal treatment or prevention of mother-to-child
transmission of HIV (7). The chemical and pharmacokinetic
properties of NVP are advantageous in these settings, particu-
larly in sub-Saharan Africa, as it can be formulated as a heat-
stable liquid preparation and has fewer drug interactions than
protease inhibitors, and its bioavailability is not affected by
food intake (20).
NVP is metabolized by a variety of cytochrome P450 (CYP)
enzymes but predominantly byCYP2B6 andCYP3A. Prior studies
have found an association between the CYP2B6 516 GT single
nucleotide polymorphism and NVP pharmacokinetics in adults
and children. Lower clearance and higher trough concentrations
have previously been observed in patients with the CYP2B6 516
TT genotype (22, 24).
The weight-adjusted oral clearance of NVP is higher in
younger children than in older children or adults. The initial FDA
pediatric dosing of 7mg/kg twice daily in children less than 8 years
of age was thus reduced to 4 mg/kg for children 8 years of age or
older. Subsequently, an alternative dosing recommendation of
150mg/m2 twice dailywas approved by the FDA (25). In resource-
limited settings, dosing based on body surface area (BSA) is not
ideal, as it requires obtaining an accurate heightmeasurement and
utilizing a mathematical calculation to obtain the appropriate
dose. An alternative approach is to dose NVP based on weight
bands, which requires no calculations and is easy to implement in
the developing world. The WHO selected weight bands rather
than age for dosing in resource-poor countries, as obtaining an
accurate age can be difficult due to poor record-keeping.
NVP has been studied extensively in adults, and multiple pop-
ulation pharmacokinetics (PK) studies have been published (1, 4,
6, 8, 11, 13, 21, 27). While many studies have looked at NVP in
HIV-infected infants, children, and adolescents (12, 15, 17, 23,
26), no comprehensive population analyses have been performed
to assess NVP across the pediatric age continuum. The current
evaluation combines PKdata from eight studies ofNVP in infants,
children, and adolescents, generating a robust NVP PK data set of
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pediatric patients from three continents. A population pharmaco-
kinetic approach was used to determine the factors affecting NVP
disposition and to compare the impact of different dosing ap-
proaches on achieving therapeutic NVP concentrations.
MATERIALS AND METHODS
NVP pharmacokinetic data were pooled from eight prior pediatric stud-
ies. Seven of the studies were protocols of the Pediatric AIDS Clinical
Trials Group/International Maternal Pediatric and Adolescent AIDS
Clinical Trials Network (PACTG/IMPAACT), namely, studies 245, 356,
366, 377, 403, P1056, and P1069. The final study was from the Children
with HIV in Africa Pharmacokinetics and Adherence of Simple Antiret-
roviral Regimens (CHAPAS). Individual study characteristics are de-
scribed below and presented in Table 1.
PACTG 245 studied NVP in HIV-1-positive children from 6 months
to 20 years of age. Children received combination therapy with NVP and
NRTIs. NVP measurements included intensive PK studies, with up to
three plasma samples collected throughout the dosing interval, and pop-
ulation pharmacokinetics, with a single sample from the dosing interval.
PACTG 356 studied NVP in HIV-1-positive children from 15 days
through 2 years of age. Children received combination therapy withNVP,
the protease inhibitor (PI) nelfinavir (NFV), and nucleoside reverse trans-
criptase inhibitors (NRTIs). NVP measurement included intensive PK
studies, with up to five plasma samples collected throughout the dosing
interval, and population pharmacokinetics, with up to two samples col-
lected in the dosing interval (2, 18).
PACTG366 studiedNVP innelfinavir and ritonavir (RTV) treatment-
experienced HIV-1-infected children from 6 months to 21 years of age.
Children received combination therapy with NVP, PIs (NFV and RTV),
and NRTIs. NVP measurement included intensive PK studies in a subset
of patients (27 total subjects) at week 4, with up to six plasma samples
collected throughout the dosing interval, and population pharmacokinet-
ics at weeks 4, 12, and 48, with one sample collected in the dosing interval
(16).
PACTG377 studiedNVP inHIV-1 positive children from4months to
17 years of age. Children received combination therapy with NVP, PIs
(NFV and RTV), and NRTIs. NVP measurements included intensive PK
studies, with up to seven plasma samples collected over the dosing inter-
val, and population pharmacokinetics, with up to two samples collected
from the dosing interval (12).
PACTG 403 studied NVP in HIV-1-positive children between 4
months and 21 years of age. Children received combination therapy with
NVP, PIs (NFV and RTV), and NRTIs. NVP measurement included in-
tensive PK studies, with up to six plasma samples collected over the dosing
interval, and population pharmacokinetics, with up to two samples col-
lected from the dosing interval (15).
IMPAACT P1056 and P1069 studiedHIV-1 infected children in Thai-
land from 6months to 13 years of age designed to assess NVP-containing
fixed-dose combination (FDC) tablets (manufactured by the Thai Gov-
ernment Pharmaceutical Organization) versus brand-name liquid for-
mulations. In both studies, children received combination therapy with
the appropriate FDC tablet (referred to as GPO-VIR), which contained
NVP and two NRTIs, and an equivalent innovator liquid formulation.
Following intensive PK sampling with seven plasma samples obtained
over the dosing interval, patients were crossed over to the alternate for-
mulation, and a repeat intensive PK profile was obtained (3, 26).
CHAPAS studied HIV-1-infected children in Zambia from 3 months
to 14 years of age to assess the Triomune tablet (Cipla Pharmaceuticals,
India). Children received combination therapy with Triomune, which
contained NVP and two NRTIs. Intensive PK profiles were determined,
with seven plasma samples collected throughout the dosing interval (17).
NVP concentrations were determined by validated high-performance
liquid chromatography methods with UV detection in the following lab-
oratories: PACTG 245, Boehringer Ingelheim Laboratory; PACTG 356
and 366, University of California San Diego Clinical Pharmacology and
Assay Laboratory, San Diego, CA; PACTG 377, University of California
San Francisco Clinical Pharmacology Laboratory, San Francisco, CA;
PACTG 403, University of Alabama at BirminghamAntiviral Pharmacol-
ogy Laboratory, Birmingham, AL; PACTG 1056 and 1069, PHPT-IRD
Laboratory, Faculty of Associated Medical Sciences, Chiang Mai Univer-
sity, ChiangMai, Thailand; and CHAPAS, RadboudUniversity Nijmegen
Medical Centre, Laboratory of Pharmacy,Nijmegen,Netherlands. All labs
participated in external quality assurance testing, including laboratory
cross-validation, with the exception of Boehringer Ingelheim. CYP2B6
genotyping was performed using real-time PCR for PACTG 366, 377, and
1069 as previously described (24).
Pharmacokinetic analysis.Using the computer program NONMEM
(version VI) with a GNU Fortran G77 compiler, concentration-time data
were fitted using a first-order conditional estimation method (FOCE)
with interaction. A one-compartment pharmacokinetic structural model
(ADVAN2, TRANS2 subroutine) with first-order absorption was used to
describe the data. NVP concentration data were log transformed (ln)
prior to analysis. An exponential-normal distribution error model was
used for intersubject variability, and a proportional residual error model
was used to describe the residual error not explained by the model or
intersubject variability.
Pharmacokinetic parameters were scaled by subject size before evalu-
ation of other potential covariates. An allometric approach was used, with
TABLE 1 Summary of study and subject demographicsa
Study
No. of NVP
subjects
Study
location
NVP
maintenance
dose
(mg/m2)
Median no. of
samples per
subject (range)
Median age (yr)
at PK visits
(range)
No. of doses in
formulationb
Median wt (kg)
at PK visits
(range)
Total no.
of
samples
245, phase I 238 U.S. 120 3 (1–6) 7.3 (1.2–19.5) 521 liquid 21.8 (7.0–61.9) 693
356, phase I/II 54 U.S. 200 6.5 (1–16) 0.3 (0.1–2.1) 144 liquid 5.9 (2.8–16.2) 376
366, phase I/II 85 U.S. 120 3 (1–9) 5.9 (0.6–17.2) 168 liquid, 13 tablet 19.5 (8.4–64.6) 305
377, phase I/II 102 U.S. 120 6 (1–20) 6.0 (0.5–14.7) 248 liquid, 38 tablet 20.9 (5.5–73.8) 698
403, phase II 16 U.S. 120 6 (1–12) 6.3 (0.5–19.3) 17 liquid, 7 tablet 22.7 (9.2–56.5) 91
CHAPAS, phase I/II 59 Zambia 150–200 7 (7–7) 6.9 (0.6–13.6) 59 Triomune 16.0 (3.4–29.0) 413
P1056, phase I/II 43 Thailand 120–200 14 (12–16) 8.3 (0.7–12.0) 43 liquid, 43 GPO-VIR 21.0 (6.4–28.9) 602
P1069, phase I/II 42 Thailand 150–200 14 (7–14) 6.1 (0.5–12.3) 41 liquid, 42 GPO-VIR 19.1 (5.9–28.6) 581
Overall 639 4 (1–20) 6.5 (0.1–19.5) 1,182 liquid, 58 tablet,
85 GPO-VIR, 59
Triomune
19.7 (2.8–73.8) 3,759
a Age and weight are representative of the first PK visit.
b “Tablet” refers to the Boehringer Ingelheim tablet; GPO-VIR and Triomune are fixed-dose combination tablets. The maximum dose was 200 mg.
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clearance (CL) being scaled by allometric weight (WT0.75) and volume of
distribution (V) being scaled by weight (WT1.0). Population (Thai or Af-
rican as compared to U.S.), gender, nelfinavir (NFV), ritonavir (RTV),
CYP2B6 genotype, and age were evaluated as potential covariates for
clearance, while various solid formulations (tablet [Boehringer-Ingel-
heim], GPO-VIR, and Triomune) were evaluated for bioavailability to
assess differences from the liquid formulation. Potential covariates were
added to the model one at a time as either a linear or nonlinear function,
with covariates that improved the model fitting by a change in the objec-
tive function of at least 4.0 (P  0.05) being retained in the initial
covariate screen. A backward elimination approach was utilized in the
multivariate assessment. Covariates found to improve the objective func-
tion by 8.0 (P0.005) or more were retained in the final model.
Agewas assessed as a potential covariate for clearance using both linear
and nonlinear maturation functions. CYP2B6 516 genotype was available
in a selected number of subjects and was modeled as poor metabolizer
(516 TT) versus all others, as well as in three groups (poor metabolizers
with the 516 GG genotype, extensive metabolizers with the 516 GT geno-
type, and unknown genotype).
To account for intrasubject variability between intensive PK visits,
interoccasion variability was modeled on clearance. Separate residual
errors were considered for U.S., Thai, and Zambian PK data. Empirical
Bayesian estimates of individual infant pharmacokinetic parameters were
generated from the finalmodel using the POSTHOC subroutine. A 1,000-
sample bootstrap assessment of the final model was performed using
Wings for NONMEM.
Monte Carlo simulations were performed using the final population
PK model to assess different dosing recommendations. Concentration
profiles for 1,000 virtual children from 0.25 to 18 years of age were simu-
lated.Weight distributions for simulations were derived fromCenters for
Disease Control and Prevention (CDC) 50th-percentile weights and a
CYP2B6 poor-metabolizer frequency identical to that in the study popu-
lation. NVP concentration profiles using theWHOweight band dosing [3
to 5.9 kg (50mg), 6 to 9.9 kg (75mg), 10 to 13.9 kg (100mg), 14 to 19.9 kg
(125 mg), 20 to 24.9 kg (150 mg), 25 to 34.9 kg (200 mg)] were compared
to the FDA dosing (NVP 150 mg/m2 with a maximum of 200 mg twice
daily). The target range for NVP trough concentrations was defined as a
minimum of 3.0 g/ml (5) with a maximum of 7.63 g/ml (95th percen-
tile of adult troughs) which corresponded to an area-under-the-curve
(AUC) target range of 42 to 108 g*h/ml, respectively (5). An additional
simulation was performed based on a population of virtual children who
were exclusively poor metabolizers (CYP2B6 516 TT genotype). RTV was
not included as a covariate for simulations because this combination at
therapeutic doses is no longer used in clinical practice.
RESULTS
Intensive and sparse pharmacokinetic data were available for 639
infants, children, and adolescents (3,759 NVP concentrations).
Table 1 summarizes patient characteristics at first PK visit.
CYP2B6 genotype information was available from 26% of the
study subjects. Among the patients with CYP2B6 genotypes, the
distribution was 11% homozygous poor metabolizers (CYP2B6
516 TT), 46% heterozygous individuals (CYP2B6 516 GT), and
42% homozygous extensive metabolizers (CYP2B6 516 GG).
Thai population, age, formulation, NFV, RTV, and CYP2B6
genotype were identified as potential covariates in the univariate
screen. Triomune formulation, age, CYP2B6 genotype, and RTV
were significant covariates retained in the final model. Separate
residual errors were assigned toU.S., Thai, andZambian datawith
an improvement of objective function.
The final population model described the data without signif-
icant bias, as shown in Fig. 1. Final model parameter and variance
estimates are shown in Table 2. All parameter estimates were
within 95% confidence intervals of the bootstrap data sets. The
residual error estimates for the Zambian and Thai data were sig-
nificantly less than that for theU.S. data, likely due to the exclusive
use of intensive PK sampling in the Zambian and Thai studies.
Age modeled as a nonlinear maturation function for clearance
(see the equations in the footnote to Table 2) provided the greatest
improvement in objective function and was utilized in the final
model. This function estimated NVP clearance at birth to be 39%
of the “mature” clearancewith a “half-life” forNVP clearance gain
of 3.2 months. The maturation function represented the effects of
age accurately, as there was no relationship between age and the
deviation from predicted (eta) clearance in the final model. As
suggested based on the maturation function parameters, the age
effect on clearancewasmodest and predominantly occurred in the
first year of life (Fig. 2A). Grouping subjects by age (2, 2 to6,
6 to12, and 12 years of age) did not demonstrate apparent age
effects on clearance normalized to BSA (Fig. 2B).
Despite the fact that CYP2B6 genotype information was avail-
able for only a limited number of subjects, CYP2B6 poor metabo-
lizer status was identified as a significant covariate for NVP clear-
ance. Figure 3 demonstrates the impact of CYP2B6 for the base
model. Apparent clearance for the homozygous CYP2B6 516 TT
FIG 1 (A) Goodness-of-fit plot. NVP concentrations from the study were compared to NONMEM individual predicted concentrations. (B) Visual predictive
plots for an NVP population PKmodel for patients not taking RTV or Triomune and with active copies of the CYP2B6 gene (extensive metabolizers). Solid lines
represent median concentrations, and dashed lines represent 97.5 and 2.5 percentiles from a Monte Carlo simulation of the final model.
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poor metabolizer genotype was 64% of the clearance for other
genotypes or the unknown genotype group. The overall propor-
tion of poor metabolizers in the population is small, and thus the
unknown group is predominately representative of patients with
the extensive metabolizer genotype (CYP2B6 516 GG and GT).
The Monte Carlo simulation comparison of AUCs and 12-h
trough concentrations obtained with the WHO weight band and
FDA dosing are shown in Fig. 4A. Although WHO weight band
dosing represents a simplified dosing structure, it performs as well
as FDA dosing, providing a similar percentage of AUC and trough
concentrations in the target range. TheWHOweight band dosing
achieved similar NVPAUCs and trough concentrations across the
pediatric age spectrum (Fig. 4B and C). The impact of CYP2B6
genotype status on AUC and trough concentrations was also as-
sessed for theWHOweight band dosing. In a population of exclu-
sively CYP2B6 poor metabolizers, the frequency of low AUC and
trough concentrations was greatly reduced, while the frequency of
above-target AUC and trough concentrations increased (Fig. 4D).
DISCUSSION
NVP remains a primary antiretroviral agent for the treatment and
prevention of HIV and AIDS in resource-limited settings. NVP
has many properties which make it useful for treating infants and
children with HIV infection. It has high and consistent bioavail-
ability, existing as both liquid and solid formulations, and is avail-
able in several fixed-dose combinations. Its relatively long half-life
makes it tolerant tominor variability in dose administration time.
However, low NVP concentrations in the presence of replicating
virus can select high-level resistance froma singlemutation; there-
fore, accurate dosing of NVP is critical (20).
The present study represents by far the largest NVP pharma-
cokinetic analysis in infants, children, and adolescents which in-
cludes data from three continents. The overall population phar-
macokinetic parameters are similar to those obtained in prior
noncompartmental analyses that have been performed on subsets
of the data used in the current analysis (15, 17, 19, 23, 26). How-
ever, the comprehensive population PK model developed in the
current analysis is better able to assess potential differences be-
tween the separate studies than comparing noncompartmental
median exposures and trough concentrations. Themedian (inter-
quartile range [IQR]) clearance in the present studywas 2.3 (1.6 to
3.3) liters/m2/h, similar to the clearance values observed by Luzur-
iaga et al. (19), which ranged from 1.4 to 2.5 liters/m2/h in the
multiple-oral-dose component of the study. However, Luzuriaga
et al. found that clearance adjusted for body surface area decreased
with increasing age, in contrast to the present study, which found
that clearance increased with age in the first year of life. Whereas
the study by Luzuriaga et al. had few subjects, the present study
represents a continuumof ages, which allowed a better assessment
of the age effect.
Prior studies have shown a potential effect of CYP2B6 gene
activity on NVP concentrations with lower clearance (24) and
TABLE 2 Population PK final parameter and standard error estimatesa
Parameter
Final
value SE
Median bootstrap estimate
(95% CI)
1 (V) 3.02 0.14 2.91 (2.69–3.18)
2 (CL) 0.20 0.0046 0.20 (0.19–0.21)
3 (Ka) 1.30 0.13 1.41 (1.18–1.68)
4 (RTV) 0.75 0.04 0.78 (0.71–0.87)
5 (CYP2B6) 0.64 0.07 0.61 (0.50–0.73)
6 (immature) 0.39 0.17 0.42 (0.10–0.99)
7 (KMAT) 3.79 0.82 4.49 (2.43–9.91)
8 (Triomune formulation) 0.58 0.03 0.56 (0.51–0.62)
Variability
Intersubject, V 28.2% 3.52% 19.11% (11.57%–26.78%)
Intersubject, CL 47.6% 1.63% 40.50% (37.42%–43.47%)
Intersubject interaction
(CL-V)
18.6% 5.11%
Interoccasion (CL) 50.7% 2.69%
Error
Proportional (US data) 21.6% 1.12% 16.7% (28.74%–68.38%)
Proportional (Thai data) 11.4% 0.57% 39.62% (37.01%–42.07%)
Proportional (African data) 13.3% 0.76% 15.13% (13.60% - 16.50%)
a Equations for clearance (CL), bioavailability (F), absorption constant (Ka), and
volume of distribution (V) used in the final model were as follows: CL (liters/h)
WT0.75245
CYP2B6 {6	 [(16) (1 e
(age  7)]}; F (%)
8
Triomune; Vd (liters)WT1; Ka (1/h)3. CYP2B6 represents the effect of the
TT genotype (poor metabolizers). Triomune 1 for the Triomune FDC formulation,
while Triomune 0 for other formulations. “Immature” represents the activity level
NVP CL at birth relative to full maturation, and KMAT is the rate constant for
acquisition of NVP CL activity.
FIG 2 Population PKmodel results. (A) Estimated NVP apparent clearance (clearance/bioavailability) versus age for patients not taking RTV or Triomune and
with active copies of the CYP2B6 gene (extensive metabolizers). The solid line represents the population-based apparent clearance profile, which was derived
using the allometrically scaled median weight for each age group (CDC 50th-percentile weight). (B) Estimated NVP apparent clearance versus age.
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higher trough concentrations (22) in homozygous poor-metabo-
lizer patients, which is supported by the present study, where poor
metabolizers had a lowerNVP clearance. TheTriomune tabletwas
a significant covariate in the model, providing a lower bioavail-
ability and yielding significantly higher clearance levels, but was
completely confounded by population. Triomune has been shown
to be bioequivalent to the innovator product in adults. So while
this difference may be due to formulation, it could also be related
to race, study design, diet, or other factors. In contrast, the GPO-
VIR tablet, whichwas evaluatedwith a crossover study design, was
not found to alter NVP bioavailability. RTV decreases the clear-
ance of NVP, consistent with its inhibition of CYP3A4 metabo-
lism. However, RTV was used in only a subset of patients in two
studies, where it was included at higher doses than when it is used
as a pharmacologic enhancer to boost antiviral drug concentra-
tions. Gender did not affect clearance in the current analysis, de-
spite a prior study byZhou et al. which found gender to affectNVP
clearance in adults; however, their study did not include body size
in themodel, whichmay account for the difference (27). Race was
not found to affect clearance in the current analysis, consistent
with the work of de Maat et al., who found no significant effect of
race (Asian, Caucasian, or African) in adults on NVP therapy (9).
Despite many years of NVP use for the treatment of pediatric
HIV infection, the labeled pediatric dose is not practical for use in
resource-poor settings. While the initial pediatric trials set NVP
doses at 120 to 200 mg/m2, the initial FDA label dose was 7 mg/kg
for young children, with a dose reduction to 4 mg/kg at 8 years of
age despite nomajor change inNVPmetabolism at that age.Many
clinicians have opted to administerNVP at 120 to 200mg/m2 (14),
andmore recently, the FDAapproved an alternative pediatric dos-
age of 150mg/m2 twice daily (25). Thus, there is a lack of a unified
dosing methodology, and the more recent BSA-based dosing re-
quires an accurate measurement of height and a calculation to
estimate BSA. WHO weight band dosing has been proposed as a
solution to the numerous problems associated with current NVP
BSA- and prior mg/kg-based dosing, offering the potential for a
simpler and more logical dosing regimen. However, since weight
band dosing represents a simplification in dosing, it recommends
the same dose for a wide range of subject weights. Thus, within a
particularweight band, smaller subjectswill have higher drug con-
centration levels and be at risk for toxicity, while larger subjects
will have lower levels and be at risk for underdosing. One might
expect fewer pediatric patients to achieve the therapeutic range
with WHO weight band dosing than with FDA dosing.
The development of a population pharmacokinetic model for
NVP allowed us to compare the expected frequency of therapeutic
concentrations with different dosing approaches using Monte
Carlo simulations. Prior studies indicated that an NVP trough
concentration of 3.0 g/ml, which corresponds to an AUC0–12 of
42 g · h/ml, is likely sufficient to ensure a sustained virologic
response (10). For the purposes of the present study, the upper
limit of the target range was defined as a trough of 7.63 g/ml
(95th percentile of adult troughs), which corresponds to an AUC
of 108 g · h/ml, although there is no consensus on a maximum
acceptable NVP concentration (5). Given the lack of evidence re-
lating a high NVP concentration to increased serious drug toxic-
ity, particularly hepatic toxicity, the current clinical emphasis is on
avoiding underdosing of NVP to prevent development of viral
drug resistance. Thus, althoughMonte Carlo simulation indicates
that CYP2B6 poor metabolizers will have higher drug levels than
extensive metabolizers, this is unlikely to result in a meaningful
increase in toxicity. It is therefore important to target dosing to-
ward CYP2B6 extensive metabolizers, who had lower trough lev-
els in the Monte Carlo simulations, to avoid underdosing and the
rapid development of high-level resistance in this group. The
Monte Carlo simulations also indicated that WHO dosing main-
tained the majority of patients in the target range for drug expo-
sure and trough level, with a similar percentage of patients in the
goal range for therapywithWHOand FDABSA dosing.While the
WHO dosing produced higher overall mean AUCs (21% higher)
and trough concentrations (13% higher) than FDA dosing, these
modest differences are unlikely to have a clinical impact. Thus,
despite the simplification of the WHO dosing guidelines, which
use identical dosing for a range of subject weights, WHO dosing
provides appropriate NVP exposure, similar to the more compli-
cated FDA dosing.
The present study developed a comprehensive population PK
model which can be updated and adjusted to specific populations.
CYP2B6 gene frequency varies greatly between different popula-
tions. The frequency of poor metabolizers varies from as little as
0.14 in Korean and Japanese populations to as much as 0.62 in
Papua NewGuinea (4); thus, significant differences in NVP expo-
sure can result. CYP2B6 differences between populations can be
addressed through population pharmacokinetic modeling and
Monte Carlo simulation, with drug dosing tailored to specific
populations. The model additionally allows targeted dosing strat-
egies based on age, race, genotype, other medications, and alter-
native formulations and thereby has the potential to improve dos-
ing recommendations for pediatric subpopulations.
The present study is limited in that NVP levels were deter-
mined at six different laboratories. However, five of the laborato-
ries participated in the same quality assurance testing. Addition-
ally, the Triomune tablet was the only formulation assessed in the
CHAPAS study. Thus, it could not be determined if changes in
apparent clearance were due to formulation, race, or other poten-
tial confounders. The CYP2B6 genotype information was also
limited, as it was unavailable for 74% of the combined study pop-
ulation; however, it still affectedNVP clearance. Finally, due to the
long half-life of NVP and limited early sampling, we were unable
FIG 3 CYP2B6 active alleles compared to deviation from expected clearance
(eta for clearance) in a population PK base model (allometric weight was the
only covariate).
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to characterize Ka and V as accurately as CL. Thus, the model has
better precision in predicting AUC thanminimumconcentration.
In conclusion, integrating data across pediatric trials into a
population pharmacokinetic analysis for NVP resulted in a robust
model that allowed characterization of age and genotype effects on
NVP clearance. The comprehensive population PK model devel-
oped can be used in combination withMonte Carlo simulation to
predict drug exposure and adjust dosing in specific populations,
thereby allowing more individualized dosing regimens. The
model also demonstrated that WHO weight band dosing recom-
mendations result inNVP troughs andAUCs comparable to those
achievedwith FDAdosing. Thus, the proposedWHOweight band
dosing represents a simplified dosing approach for NVP in re-
source-limited countries.
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